Physician profile
Nan Nelson
NPI 1396816625
$333.06
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $80.39 | 2021 | |
| Alkermes, INC. | $60.93 | 2021 | |
| Validus Pharmaceuticals LLC | $60.05 | 2021 | |
| Neos Therapeutics, Lp | $38.83 | 2021 | |
| Lundbeck LLC | $29.22 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.82 | 2021 | |
| Abbvie INC. | $12.99 | 2021 | |
| Eisai INC. | $11.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.